Bioorganic Chemistry最新文献_第9页

Issue TOC TOC问题

IF 4.7 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Bioorganic Chemistry

Pub Date : 2026-01-17 DOI: 10.1016/S0045-2068(26)00035-0

引用次数: 0

An insight into the anticancer potential of sulfonated styrylquinazolines as multifunctional agents targeting microtubules. 磺化苯基喹唑啉作为靶向微管的多功能药物的抗癌潜力。

IF 4.7 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Bioorganic Chemistry

Pub Date : 2026-01-17 DOI: 10.1016/j.bioorg.2026.109517

Patryk Rurka , Jacek Mularski , Patryk Ziola , Anna Boguszewska-Czubara , Josef Jampilek , Anna Mrozek-Wilczkiewicz , Katarzyna Malarz

Developing new microtubule-targeting agents is extremely important for cancer treatment. One of the goals is to overcome drug resistance, since these agents can cause mitotic arrest and thus cause impairment to cell signaling. Despite this, there are many gaps in our understanding of the complex actions of such agents. In this study, we report the synthesis and biological evaluation of a novel series of sulfonic styrylquinazoline derivatives, featuring three quinazoline core variants: unsubstituted, 6-chloro, and 7-chloro. Antiproliferative assays revealed that the 6-chloro derivative exhibited potent sub-micromolar activity against glioblastoma (GBM) and leukemia cell lines, while the 7-chloro analogs showed selective activity against leukemia cells. Importantly, the compounds were selective against normal cells. Further detailed molecular studies revealed that the most active compounds caused cell cycle arrest in the G2/M phase and disrupted microtubule polymerization–depolymerization dynamics, thereby affecting intracellular signaling pathways. Mechanistic studies showed the influence of the derivatives on cell cycle-related proteins (Aurora A and cyclin B1) and the inhibition of EGFR/Akt/mTOR and EGFR/Ras cell signaling. Cell death was induced primarily through apoptosis and potentially via autophagy, depending on the type of cell line. In addition, detailed computational studies have established a plausible binding model for these derivatives at the cevipabulin site of tubulin. Finally, physicochemical properties were determined to ensure adequate bioavailability, also toxicity and therapeutic efficacy were studied on an in vivo model. Notably, the 6-Cl derivative showed significantly better therapeutic efficacy than osimertinib on the zebrafish GBM xenograft model.

开发新的微管靶向药物对癌症治疗至关重要。其中一个目标是克服耐药性，因为这些药物可以引起有丝分裂阻滞，从而导致细胞信号的损害。尽管如此，我们对这类试剂的复杂作用的理解仍有许多空白。在这项研究中，我们报道了一系列新的磺酸苯基喹唑啉衍生物的合成和生物学评价，这些衍生物具有三种喹唑啉核心变体：未取代的、6-氯的和7-氯的。抗增殖实验表明，6-氯衍生物对胶质母细胞瘤（GBM）和白血病细胞系具有亚微摩尔活性，而7-氯类似物对白血病细胞具有选择性活性。重要的是，这些化合物对正常细胞具有选择性。进一步详细的分子研究表明，最活跃的化合物导致细胞周期阻滞在G2/M期，破坏微管聚合-解聚动力学，从而影响细胞内信号通路。机制研究表明，衍生物影响细胞周期相关蛋白（Aurora A和cyclin B1），抑制EGFR/Akt/mTOR和EGFR/Ras细胞信号传导。细胞死亡主要通过凋亡诱导，也可能通过自噬诱导，这取决于细胞系的类型。此外，详细的计算研究已经建立了这些衍生物在微管蛋白的cevipabulin位点的合理结合模型。最后，测定其理化性质以确保充分的生物利用度，并在体内模型上研究其毒性和治疗效果。值得注意的是，6-Cl衍生物对斑马鱼GBM异种移植模型的治疗效果明显优于奥西替尼。

{"title":"An insight into the anticancer potential of sulfonated styrylquinazolines as multifunctional agents targeting microtubules.","authors":"Patryk Rurka , Jacek Mularski , Patryk Ziola , Anna Boguszewska-Czubara , Josef Jampilek , Anna Mrozek-Wilczkiewicz , Katarzyna Malarz","doi":"10.1016/j.bioorg.2026.109517","DOIUrl":"10.1016/j.bioorg.2026.109517","url":null,"abstract":"<div><div>Developing new microtubule-targeting agents is extremely important for cancer treatment. One of the goals is to overcome drug resistance, since these agents can cause mitotic arrest and thus cause impairment to cell signaling. Despite this, there are many gaps in our understanding of the complex actions of such agents. In this study, we report the synthesis and biological evaluation of a novel series of sulfonic styrylquinazoline derivatives, featuring three quinazoline core variants: unsubstituted, 6-chloro, and 7-chloro. Antiproliferative assays revealed that the 6-chloro derivative exhibited potent sub-micromolar activity against glioblastoma (GBM) and leukemia cell lines, while the 7-chloro analogs showed selective activity against leukemia cells. Importantly, the compounds were selective against normal cells. Further detailed molecular studies revealed that the most active compounds caused cell cycle arrest in the G2/M phase and disrupted microtubule polymerization–depolymerization dynamics, thereby affecting intracellular signaling pathways. Mechanistic studies showed the influence of the derivatives on cell cycle-related proteins (Aurora A and cyclin B1) and the inhibition of EGFR/Akt/mTOR and EGFR/Ras cell signaling. Cell death was induced primarily through apoptosis and potentially <em>via</em> autophagy, depending on the type of cell line. In addition, detailed computational studies have established a plausible binding model for these derivatives at the cevipabulin site of tubulin. Finally, physicochemical properties were determined to ensure adequate bioavailability, also toxicity and therapeutic efficacy were studied on an <em>in vivo</em> model. Notably, the 6-Cl derivative showed significantly better therapeutic efficacy than osimertinib on the zebrafish GBM xenograft model.</div></div>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"170 ","pages":"Article 109517"},"PeriodicalIF":4.7,"publicationDate":"2026-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146016741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

4-[(Aryloylhydrazineylidene)methyl]-N-phenylbenzamides as a new class of antimycobacterial agents: design, synthesis and biological evaluation 4-[（芳基肼基）甲基]- n -苯基苯并胺类新型抗菌药物的设计、合成及生物学评价。

IF 4.7 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Bioorganic Chemistry

Pub Date : 2026-01-17 DOI: 10.1016/j.bioorg.2026.109510

Václav Pflégr , Apolena Koklarová , Jiřina Stolaříková , Gabriela Svobodová , Martin Ambrož , Monika Záhorszká , Jana Korduláková , Martin Krátký

A novel series of 4-[(aryloylhydrazineylidene)methyl]-N-phenylbenzamides was designed, synthesized, and evaluated as potential antitubercular agents. The compounds were obtained through a two-step synthesis from pyridine-4-carbohydrazide or 3,5-dinitrobenzohydrazide precursors, using 4-formylbenzoic acid as a molecular linker and various 4-substituted anilines to fine-tune lipophilicity and electronic properties. All derivatives were tested in vitro against Mycobacterium tuberculosis (Mtb), M. avium, and M. kansasii, including multidrug-resistant clinical isolates. Several amides displayed potent and selective activity against Mtb, with minimum inhibitory concentrations ≤0.03 μM, surpassing isoniazid (INH). Structure–activity relationship analysis revealed that INH-based derivatives generally outperformed their 3,5-dinitrobenzohydrazide counterparts and that halogen or electron-donating substituents enhanced potency. Mode-of-action studies using metabolic labeling and enzyme overexpression experiments indicated that the most active compounds interfere with mycolic acid biosynthesis, consistent with an InhA-related mechanism. Cytotoxicity evaluation in rat precision-cut liver slices confirmed good tolerance. Overall, these benzamide–hydrazone hybrids represent a promising chemotype, offering a valuable platform for further optimization toward next-generation antitubercular drug candidates.

设计、合成了一系列新的[（芳基肼基）甲基]- n -苯基苯并胺，并对其作为潜在的抗结核药物进行了评价。以4-甲酰基苯甲酸为分子连接剂，以不同的4-取代苯胺调节亲脂性和电子性质，以吡啶-4-碳酰肼或3,5-二硝基苯酰肼为前体，经两步合成得到了上述化合物。对所有衍生物进行了抗结核分枝杆菌（Mtb）、鸟分枝杆菌和堪萨斯分枝杆菌的体外试验，包括耐多药临床分离株。几种酰胺对Mtb表现出较强的选择性抑制活性，最小抑制浓度≤0.03 μM，超过异烟肼（INH）。构效关系分析表明，inh基衍生物的效价普遍优于3,5-二硝基苯并肼衍生物，而卤素或给电子取代基的效价提高。利用代谢标记和酶过表达实验进行的作用模式研究表明，最活跃的化合物干扰霉菌酸的生物合成，与ha相关的机制一致。对大鼠精确切肝片的细胞毒性评价证实了良好的耐受性。总的来说，这些苯酰胺-腙杂交体代表了一种有前途的化学型，为进一步优化下一代抗结核候选药物提供了有价值的平台。

{"title":"4-[(Aryloylhydrazineylidene)methyl]-N-phenylbenzamides as a new class of antimycobacterial agents: design, synthesis and biological evaluation","authors":"Václav Pflégr , Apolena Koklarová , Jiřina Stolaříková , Gabriela Svobodová , Martin Ambrož , Monika Záhorszká , Jana Korduláková , Martin Krátký","doi":"10.1016/j.bioorg.2026.109510","DOIUrl":"10.1016/j.bioorg.2026.109510","url":null,"abstract":"<div><div>A novel series of 4-[(aryloylhydrazineylidene)methyl]-<em>N</em>-phenylbenzamides was designed, synthesized, and evaluated as potential antitubercular agents. The compounds were obtained through a two-step synthesis from pyridine-4-carbohydrazide or 3,5-dinitrobenzohydrazide precursors, using 4-formylbenzoic acid as a molecular linker and various 4-substituted anilines to fine-tune lipophilicity and electronic properties. All derivatives were tested <em>in vitro</em> against <em>Mycobacterium tuberculosis</em> (<em>Mtb</em>), <em>M. avium</em>, and <em>M. kansasii</em>, including multidrug-resistant clinical isolates. Several amides displayed potent and selective activity against <em>Mtb</em>, with minimum inhibitory concentrations ≤0.03 μM, surpassing isoniazid (INH). Structure–activity relationship analysis revealed that INH-based derivatives generally outperformed their 3,5-dinitrobenzohydrazide counterparts and that halogen or electron-donating substituents enhanced potency. Mode-of-action studies using metabolic labeling and enzyme overexpression experiments indicated that the most active compounds interfere with mycolic acid biosynthesis, consistent with an InhA-related mechanism. Cytotoxicity evaluation in rat precision-cut liver slices confirmed good tolerance. Overall, these benzamide–hydrazone hybrids represent a promising chemotype, offering a valuable platform for further optimization toward next-generation antitubercular drug candidates.</div></div>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"170 ","pages":"Article 109510"},"PeriodicalIF":4.7,"publicationDate":"2026-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146027908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel 5,7-Diazaindole-based ERK5 inhibitor induces endoplasmic reticulum stress and mitochondrial apoptosis in non-small cell lung Cancer 新型5,7-二氮唑类ERK5抑制剂诱导非小细胞肺癌内质网应激和线粒体凋亡。

IF 4.7 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Bioorganic Chemistry

Pub Date : 2026-01-16 DOI: 10.1016/j.bioorg.2026.109512

Binbin Tian , Yunjie Li , Pengyu Xue , Renhao Chen , Shuo Lv , Luqian He , Gaoyang Lin , Jun Xiao , Lin Long , Guorui Cao , Chuanlong Guo , Longjiang Huang

The extracellular signal-regulated kinase 5 (ERK5) signaling pathway represents a promising therapeutic target for non-small cell lung cancer (NSCLC), yet the development of potent and selective inhibitors remains a challenge. Leveraging the 5,7-diazaindole scaffold, a privileged structure in kinase inhibitor discovery, we designed, synthesized, and evaluated a novel series of derivatives as potential ERK5 inhibitors. Among them, compound I1 emerged as the most potent candidate, demonstrating significant anti-proliferative activity against A549 human lung cancer cells with an IC₅₀ of 40.1 μM. Critically, an in vitro kinase assay confirmed that I1 is a direct ERK5 inhibitor, exhibiting potent inhibition of purified ERK5 kinase activity with an IC₅₀ of 403.4 nM. Structure-activity relationship (SAR) studies underscored the critical importance of the unsaturated 1,2,3,6-tetrahydropyridine ring, the amide carbonyl group, and the N1H moiety for optimal activity. Molecular docking revealed that I1 binds robustly within the ERK5 ATP-binding site (PDB: 6HKM), forming key hydrogen bonds with Met140, Asp138, and Asp200, and exhibiting a more favorable binding mode than its analogues. Mechanistic studies indicated that I1 functions as a direct ERK5 inhibitor, suppressing both ERK5 phosphorylation and total protein expression. This ERK5 inhibition triggered a multi-modal anti-tumor mechanism, including the induction of endoplasmic reticulum stress, mitochondrial dysfunction (characterized by reactive oxygen species accumulation and loss of membrane potential), and ultimately, activation of the mitochondrial apoptotic pathway. Importantly, I1 exhibited significant dose-dependent tumor growth suppression in a Lewis lung carcinoma mouse model without causing observable toxicity, highlighting its potential as a promising lead compound for targeted NSCLC therapy.

细胞外信号调节激酶5 （ERK5）信号通路是非小细胞肺癌（NSCLC）的一个有希望的治疗靶点，但开发有效的选择性抑制剂仍然是一个挑战。利用5,7-二氮吲哚支架（激酶抑制剂发现中的特权结构），我们设计、合成并评估了一系列新的衍生物作为潜在的ERK5抑制剂。其中，化合物I1成为最有效的候选者，对A549人肺癌细胞表现出显著的抗增殖活性，IC₅0为40.1 μM。关键的是，一项体外激酶试验证实I1是一种直接的ERK5抑制剂，表现出对纯化ERK5激酶活性的有效抑制，IC₅0为403.4 nM。构效关系（SAR）研究强调了不饱和1,2,3,6-四氢吡啶环、酰胺羰基和N1H部分对最佳活性的至关重要。分子对接发现I1在ERK5 atp结合位点（PDB: 6HKM）内稳定结合，与Met140、Asp138和Asp200形成关键氢键，并表现出比其类似物更有利的结合模式。机制研究表明I1作为ERK5直接抑制剂，抑制ERK5磷酸化和总蛋白表达。这种ERK5抑制触发了多模式的抗肿瘤机制，包括诱导内质网应激、线粒体功能障碍（以活性氧积累和膜电位丧失为特征），并最终激活线粒体凋亡途径。重要的是，I1在Lewis肺癌小鼠模型中表现出明显的剂量依赖性肿瘤生长抑制，而没有引起可观察到的毒性，这突出了其作为靶向非小细胞肺癌治疗先导化合物的潜力。

{"title":"Novel 5,7-Diazaindole-based ERK5 inhibitor induces endoplasmic reticulum stress and mitochondrial apoptosis in non-small cell lung Cancer","authors":"Binbin Tian , Yunjie Li , Pengyu Xue , Renhao Chen , Shuo Lv , Luqian He , Gaoyang Lin , Jun Xiao , Lin Long , Guorui Cao , Chuanlong Guo , Longjiang Huang","doi":"10.1016/j.bioorg.2026.109512","DOIUrl":"10.1016/j.bioorg.2026.109512","url":null,"abstract":"<div><div>The extracellular signal-regulated kinase 5 (ERK5) signaling pathway represents a promising therapeutic target for non-small cell lung cancer (NSCLC), yet the development of potent and selective inhibitors remains a challenge. Leveraging the 5,7-diazaindole scaffold, a privileged structure in kinase inhibitor discovery, we designed, synthesized, and evaluated a novel series of derivatives as potential ERK5 inhibitors. Among them, compound <strong>I1</strong> emerged as the most potent candidate, demonstrating significant anti-proliferative activity against A549 human lung cancer cells with an IC₅₀ of 40.1 μM. Critically, an <em>in vitro</em> kinase assay confirmed that <strong>I1</strong> is a direct ERK5 inhibitor, exhibiting potent inhibition of purified ERK5 kinase activity with an IC₅₀ of 403.4 nM. Structure-activity relationship (SAR) studies underscored the critical importance of the unsaturated 1,2,3,6-tetrahydropyridine ring, the amide carbonyl group, and the N1<img>H moiety for optimal activity. Molecular docking revealed that <strong>I1</strong> binds robustly within the ERK5 ATP-binding site (PDB: <span><span>6HKM</span><svg><path></path></svg></span>), forming key hydrogen bonds with Met140, Asp138, and Asp200, and exhibiting a more favorable binding mode than its analogues. Mechanistic studies indicated that <strong>I1</strong> functions as a direct ERK5 inhibitor, suppressing both ERK5 phosphorylation and total protein expression. This ERK5 inhibition triggered a multi-modal anti-tumor mechanism, including the induction of endoplasmic reticulum stress, mitochondrial dysfunction (characterized by reactive oxygen species accumulation and loss of membrane potential), and ultimately, activation of the mitochondrial apoptotic pathway. Importantly, <strong>I1</strong> exhibited significant dose-dependent tumor growth suppression in a Lewis lung carcinoma mouse model without causing observable toxicity, highlighting its potential as a promising lead compound for targeted NSCLC therapy.</div></div>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"170 ","pages":"Article 109512"},"PeriodicalIF":4.7,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146027915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Construction of the chiral 24R-OH squalamine intermediate by an engineered ketoreductase from Rhodococcus sp. 红球菌工程酮还原酶构建手性24R-OH角鲨胺中间体。

IF 4.7 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Bioorganic Chemistry

Pub Date : 2026-01-16 DOI: 10.1016/j.bioorg.2026.109515

Hong Li, Zhen Du, Yanxia Lin, Zhe Zhang, Min Wu, Yihua Zhong, Shan Li, Lei Zhang

The 24R-OH construction remains a bottleneck in squalamine synthesis. In this study, a ketoreductase from Rhodococcus sp. was screened out, which could catalyze the conversion of 7α-hydroxy-5α-cholestan-3, 24-dione to the key intermediate (7α, 24R)-dihydroxy-5α-cholestan-3-one (24R-OH). A mechanism-driven computational design strategy was employed, and regional engineering targeting the substrate channel (D42A), flexible regions (P89G, P158S), and a structural stabilization zone (A327P) was conducted to generate the quadruple mutant D42A/P89G/P158S/A327P. Under the reaction conditions at 10 mg/mL substrate and 25% (v/v) isopropanol, the mutant achieved a conversion of 99.1% with a diastereomeric excess of >99.9%. Further investigation through molecular dynamics simulations, free energy calculations, and hydrogen-bonding network analysis revealed that the mutation facilitated substrate access and product release while stabilizing the protein structure. This study provides a robust and industrially viable biosynthetic route for efficiently producing 24R-OH, the key intermediate in the squalamine synthesis.

24R-OH结构仍然是角鲨胺合成的瓶颈。本研究从红球菌中筛选出一种酮还原酶，该酶可催化7α-羟基-5α-胆甾醇- 3,24 -二酮转化为关键中间体(7α, 24R)-二羟基-5α-胆甾醇-3-one （24R- oh）。采用机制驱动的计算设计策略，针对衬底通道（D42A）、柔性区域（P89G、P158S）和结构稳定区（A327P）进行区域工程，生成四重突变体D42A/P89G/P158S/A327P。在10 mg/mL底物和25% （v/v）异丙醇的反应条件下，突变体的转化率为99.1%，非对映异构体过剩率为99.9%。通过分子动力学模拟、自由能计算和氢键网络分析的进一步研究表明，该突变促进了底物进入和产物释放，同时稳定了蛋白质结构。该研究为高效生产角鲨胺合成的关键中间体24R-OH提供了一条可靠且工业上可行的生物合成途径。

{"title":"Construction of the chiral 24R-OH squalamine intermediate by an engineered ketoreductase from Rhodococcus sp.","authors":"Hong Li, Zhen Du, Yanxia Lin, Zhe Zhang, Min Wu, Yihua Zhong, Shan Li, Lei Zhang","doi":"10.1016/j.bioorg.2026.109515","DOIUrl":"10.1016/j.bioorg.2026.109515","url":null,"abstract":"<div><div>The 24<em>R</em>-OH construction remains a bottleneck in squalamine synthesis. In this study, a ketoreductase from <em>Rhodococcus</em> sp. was screened out, which could catalyze the conversion of 7<em>α</em>-hydroxy-5<em>α</em>-cholestan-3, 24-dione to the key intermediate (7<em>α</em>, 24<em>R</em>)-dihydroxy-5<em>α</em>-cholestan-3-one (24<em>R</em>-OH). A mechanism-driven computational design strategy was employed, and regional engineering targeting the substrate channel (D42A), flexible regions (P89G, P158S), and a structural stabilization zone (A327P) was conducted to generate the quadruple mutant D42A/P89G/P158S/A327P. Under the reaction conditions at 10 mg/mL substrate and 25% (<em>v</em>/v) isopropanol, the mutant achieved a conversion of 99.1% with a diastereomeric excess of >99.9%. Further investigation through molecular dynamics simulations, free energy calculations, and hydrogen-bonding network analysis revealed that the mutation facilitated substrate access and product release while stabilizing the protein structure. This study provides a robust and industrially viable biosynthetic route for efficiently producing 24<em>R</em>-OH, the key intermediate in the squalamine synthesis.</div></div>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"170 ","pages":"Article 109515"},"PeriodicalIF":4.7,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146027958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

(Z)-4-(substituted benzylidene)-2-phenyl-1H-imidazol-5(4H)-ones are sensitive to tyrosinases of different origins: In vitro and in vivo insights (Z)-4-（取代苄基）-2-苯基- 1h -咪唑-5(4H)- 1对不同来源的酪氨酸酶敏感：体外和体内观察

IF 4.7 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Bioorganic Chemistry

Pub Date : 2026-01-16 DOI: 10.1016/j.bioorg.2026.109514

Hee Jin Jung , Hyeon Seo Park , Yeonsoo Jeong , Hyejin Kang , Minchang Kim , Hyunju Lee , Hyunhee Ju , Hae Young Chung , Yujin Park , Hyung Ryong Moon

We used Staudinger azide reduction and Knoevenagel condensation reactions to synthesize 13 different (Z)-4-(substituted benzylidene)-2-phenyl-1H-imidazol-5(4H)-one (BPIO) analogs (1−13) that hybridize a β-phenyl-α,β-unsaturated carbonyl scaffold with a 2-phenyl-1H-imidazol-5(4H)-one moiety, as potential tyrosinase (TYR) inhibitors. Eight BPIO analogs showed mushroom TYR (mTYR) inhibitory efficacy comparable to or superior to that of kojic acid (KA). Kinetic analyses were performed to determine the mTYR inhibition mechanism of BPIO analogs. Kinetic findings were supported by docking experiments. The cellular TYR inhibitory activity of analogs 6, 8, 10, and 11 was shown to be responsible for their anti-melanogenic potency in B16F10 cells. Analog 8, which showed limited inhibitory activity against mTYR, potently inhibited melanin biosynthesis in B16F10 cells. This result may be due to structural differences between B16F10 TYR and mTYR. Several tested analogs exhibited high potency in a zebrafish embryo depigmentation assay, with analog 1 potently producing nearly pigment-free zebrafish larvae at 100 μM. The results of this study suggest that these BPIO analogs are sensitive to structural differences between TYRs from different organisms, and that melanin inhibitory activities of individual BPIO analogs are highly specific to the TYR used. Individual BPIO analogs may therefore selectively inhibit TYRs from different organisms.

我们使用Staudinger叠氮化物还原和Knoevenagel缩合反应合成了13种不同的(Z)-4-（取代苄基）-2-苯基- 1h -咪唑-5(4H)- 1 （BPIO）类似物（1−13），它们将β-苯基-α，β-不饱和羰基支架与2-苯基- 1h -咪唑-5(4H)- 1片段杂交，作为潜在的酪氨酸酶（TYR）抑制剂。8种BPIO类似物对蘑菇TYR （mTYR）的抑制效果与曲酸（KA）相当或优于曲酸。动力学分析确定了BPIO类似物的mTYR抑制机制。动力学发现得到了对接实验的支持。类似物6、8、10和11的细胞TYR抑制活性被证明是它们在B16F10细胞中抗黑素生成效力的原因。类似物8对mTYR的抑制活性有限，但能有效抑制B16F10细胞的黑色素合成。这一结果可能是由于B16F10 TYR和mTYR之间的结构差异。几种被测试的类似物在斑马鱼胚胎脱色试验中表现出很高的效力，其中类似物1在100 μM下可以产生几乎无色素的斑马鱼幼虫。本研究结果表明，这些BPIO类似物对来自不同生物的TYR之间的结构差异敏感，并且单个BPIO类似物的黑色素抑制活性对所使用的TYR具有高度特异性。因此，单个BPIO类似物可能选择性地抑制来自不同生物体的tyr。

{"title":"(Z)-4-(substituted benzylidene)-2-phenyl-1H-imidazol-5(4H)-ones are sensitive to tyrosinases of different origins: In vitro and in vivo insights","authors":"Hee Jin Jung , Hyeon Seo Park , Yeonsoo Jeong , Hyejin Kang , Minchang Kim , Hyunju Lee , Hyunhee Ju , Hae Young Chung , Yujin Park , Hyung Ryong Moon","doi":"10.1016/j.bioorg.2026.109514","DOIUrl":"10.1016/j.bioorg.2026.109514","url":null,"abstract":"<div><div>We used Staudinger azide reduction and Knoevenagel condensation reactions to synthesize 13 different (<em>Z</em>)-4-(substituted benzylidene)-2-phenyl-1<em>H</em>-imidazol-5(4<em>H</em>)-one (BPIO) analogs (<strong>1</strong>−<strong>13</strong>) that hybridize a β-phenyl-α,β-unsaturated carbonyl scaffold with a 2-phenyl-1<em>H</em>-imidazol-5(4<em>H</em>)-one moiety, as potential tyrosinase (TYR) inhibitors. Eight BPIO analogs showed mushroom TYR (<em>m</em>TYR) inhibitory efficacy comparable to or superior to that of kojic acid (KA). Kinetic analyses were performed to determine the <em>m</em>TYR inhibition mechanism of BPIO analogs. Kinetic findings were supported by docking experiments. The cellular TYR inhibitory activity of analogs <strong>6</strong>, <strong>8</strong>, <strong>10</strong>, and <strong>11</strong> was shown to be responsible for their anti-melanogenic potency in B16F10 cells. Analog <strong>8</strong>, which showed limited inhibitory activity against <em>m</em>TYR, potently inhibited melanin biosynthesis in B16F10 cells. This result may be due to structural differences between B16F10 TYR and <em>m</em>TYR. Several tested analogs exhibited high potency in a zebrafish embryo depigmentation assay, with analog <strong>1</strong> potently producing nearly pigment-free zebrafish larvae at 100 μM. The results of this study suggest that these BPIO analogs are sensitive to structural differences between TYRs from different organisms, and that melanin inhibitory activities of individual BPIO analogs are highly specific to the TYR used. Individual BPIO analogs may therefore selectively inhibit TYRs from different organisms.</div></div>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"170 ","pages":"Article 109514"},"PeriodicalIF":4.7,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146034946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antifungal activity of AR-12 and its derivatives against clinically relevant fusarium solani isolates in keratitis AR-12及其衍生物对临床相关的角膜炎镰刀菌的抗真菌活性

IF 4.7 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Bioorganic Chemistry

Pub Date : 2026-01-16 DOI: 10.1016/j.bioorg.2026.109516

Yihui Ma , Lei Han , Yujuan Wang , Shuiping Jiang , Xiaofang Gao

Keratitis infections caused by Fusarium species are on the rise globally, posing a significant challenge for treatment due to the intrinsic resistance mechanisms associated with these fungi. AR-12 (OSU-03012) is a celecoxib-derived protein kinase inhibitor with characteristic scaffold of 1,5-diaryl-3-trifluoropyrazole, originally developed as an antitumor agent that reached Phase I clinical trials, but has since shown activity against a broad spectrum of pathogens, including fungi, bacteria, and viruses. In an effort to expand the therapeutic options available for Fusarium keratitis, this study evaluated the antifungal efficacy of AR-12 against Fusarium solani isolates responsible for keratitis infections. The results showed that the minimum inhibitory concentration (MIC) of AR-12 against these isolates ranged from 2 to 8 μg/mL, comparable to that of the control antifungal agent voriconazole. Subsequently, we performed systematic chemical modifications of AR-12 and investigate the structure-activity relationships (SAR). Moreover, solubility measurements of the active derivatives identified compound B8 as exhibiting the optimal balance between antifungal efficacy and hydrophobicity. Further investigations with B8 revealed morphological changes and the disruption of the cell membrane. This study underscores the potential of AR-12's chemical scaffold as a valuable foundation for the development of potent antifungal drugs.

镰刀菌引起的角膜炎感染在全球呈上升趋势，由于与这些真菌相关的内在耐药机制，对治疗构成了重大挑战。AR-12 （OSU-03012）是一种塞来昔布衍生的蛋白激酶抑制剂，具有1,5-二芳基-3-三氟吡唑的特征支架，最初是作为抗肿瘤药物开发的，已达到I期临床试验，但后来显示出对多种病原体的活性，包括真菌、细菌和病毒。为了扩大角膜炎镰刀菌的治疗选择，本研究评估了AR-12对角膜炎感染的梭兰镰刀菌分离株的抗真菌效果。结果表明，AR-12的最低抑菌浓度（MIC）为2 ~ 8 μg/mL，与对照抗真菌剂伏立康唑相当。随后，我们对AR-12进行了系统的化学修饰，并研究了构效关系（SAR）。此外，活性衍生物的溶解度测量表明，化合物B8在抗真菌功效和疏水性之间表现出最佳的平衡。对B8的进一步研究显示形态学改变和细胞膜破坏。这项研究强调了AR-12的化学支架作为开发有效抗真菌药物的宝贵基础的潜力。

{"title":"Antifungal activity of AR-12 and its derivatives against clinically relevant fusarium solani isolates in keratitis","authors":"Yihui Ma , Lei Han , Yujuan Wang , Shuiping Jiang , Xiaofang Gao","doi":"10.1016/j.bioorg.2026.109516","DOIUrl":"10.1016/j.bioorg.2026.109516","url":null,"abstract":"<div><div>Keratitis infections caused by <em>Fusarium</em> species are on the rise globally, posing a significant challenge for treatment due to the intrinsic resistance mechanisms associated with these fungi. AR-12 (OSU-03012) is a celecoxib-derived protein kinase inhibitor with characteristic scaffold of 1,5-diaryl-3-trifluoropyrazole, originally developed as an antitumor agent that reached Phase I clinical trials, but has since shown activity against a broad spectrum of pathogens, including fungi, bacteria, and viruses. In an effort to expand the therapeutic options available for <em>Fusarium</em> keratitis, this study evaluated the antifungal efficacy of AR-12 against <em>Fusarium solani</em> isolates responsible for keratitis infections. The results showed that the minimum inhibitory concentration (MIC) of AR-12 against these isolates ranged from 2 to 8 μg/mL, comparable to that of the control antifungal agent voriconazole. Subsequently, we performed systematic chemical modifications of AR-12 and investigate the structure-activity relationships (SAR). Moreover, solubility measurements of the active derivatives identified compound <strong>B8</strong> as exhibiting the optimal balance between antifungal efficacy and hydrophobicity. Further investigations with <strong>B8</strong> revealed morphological changes and the disruption of the cell membrane. This study underscores the potential of AR-12's chemical scaffold as a valuable foundation for the development of potent antifungal drugs.</div></div>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"170 ","pages":"Article 109516"},"PeriodicalIF":4.7,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146035024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Engineered N-terminal modified α/β-hybrid peptides with enhanced selectivity and stability: Multi-target antibacterials for combating MRSA 具有增强选择性和稳定性的工程n端修饰α/β杂化肽：用于对抗MRSA的多靶点抗菌药物

IF 4.7 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Bioorganic Chemistry

Pub Date : 2026-01-14 DOI: 10.1016/j.bioorg.2026.109495

Jyoti Kumari , Aminur Rahman Sarkar , Beenish Rashid , Arti Rathore , Shifa Firdous , Rubina Chowdhary , Biplab Sarkar , Rakshit Manhas , Rajkishor Rai , Avisek Mahapa

Cytotoxicity, hemolytic effects, poor enzymatic stability and high manufacturing costs are the major challenges associated with the clinical development of antibacterial peptides. We designed and synthesized a new series of short cationic α/β-hybrid peptides (TH-01, TH-02, and TH-03) by incorporating a urea bond in place of a traditional amide bond and an N-terminal THPA moiety. These modifications were strategically incorporated to enhance antibacterial activity, structural stability, and cellular selectivity, also allowing detailed mechanistic investigation. Remarkably, the synthesized peptides retained antimicrobial activity, achieving an MIC of 1.5–12.5 μM (0.9–7.5 μg/ml) against MRSA, along with enhanced selectivity and stability. The subsequent mechanistic studies revealed that these peptides showed bactericidal activity by utilizing multi-targeted mechanisms, including lysis of the cell membrane, interaction with genomic DNA and induction of reactive oxygen species. Overall, this class of α/β-hybrid peptides represents a promising advancement toward the development of short, stable, and selective antimicrobial agents, offering valuable new strategies for combating antimicrobial resistance.

细胞毒性、溶血作用、酶稳定性差和制造成本高是抗菌肽临床开发的主要挑战。我们设计并合成了一系列新的短阳离子α/β-杂化肽（TH-01， TH-02和TH-03），通过尿素键代替传统的酰胺键和n端THPA片段。这些修饰被战略性地加入以增强抗菌活性、结构稳定性和细胞选择性，也允许详细的机制研究。值得注意的是，合成的肽保留了抗菌活性，对MRSA的MIC为1.5-12.5 μM (0.9-7.5 μg/ml)，同时增强了选择性和稳定性。随后的机制研究表明，这些肽通过多靶点机制显示出杀菌活性，包括细胞膜的裂解、与基因组DNA的相互作用和活性氧的诱导。总的来说，这类α/β-杂化肽代表了开发短、稳定和选择性抗菌药物的有希望的进展，为对抗抗菌药物耐药性提供了有价值的新策略。

{"title":"Engineered N-terminal modified α/β-hybrid peptides with enhanced selectivity and stability: Multi-target antibacterials for combating MRSA","authors":"Jyoti Kumari , Aminur Rahman Sarkar , Beenish Rashid , Arti Rathore , Shifa Firdous , Rubina Chowdhary , Biplab Sarkar , Rakshit Manhas , Rajkishor Rai , Avisek Mahapa","doi":"10.1016/j.bioorg.2026.109495","DOIUrl":"10.1016/j.bioorg.2026.109495","url":null,"abstract":"<div><div>Cytotoxicity, hemolytic effects, poor enzymatic stability and high manufacturing costs are the major challenges associated with the clinical development of antibacterial peptides. We designed and synthesized a new series of short cationic α/β-hybrid peptides (TH-01, TH-02, and TH-03) by incorporating a urea bond in place of a traditional amide bond and an N-terminal THPA moiety. These modifications were strategically incorporated to enhance antibacterial activity, structural stability, and cellular selectivity, also allowing detailed mechanistic investigation. Remarkably, the synthesized peptides retained antimicrobial activity, achieving an MIC of 1.5–12.5 μM (0.9–7.5 μg/ml) against MRSA, along with enhanced selectivity and stability. The subsequent mechanistic studies revealed that these peptides showed bactericidal activity by utilizing multi-targeted mechanisms, including lysis of the cell membrane, interaction with genomic DNA and induction of reactive oxygen species. Overall, this class of α/β-hybrid peptides represents a promising advancement toward the development of short, stable, and selective antimicrobial agents, offering valuable new strategies for combating antimicrobial resistance.</div></div>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"170 ","pages":"Article 109495"},"PeriodicalIF":4.7,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146035064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Copper(II)-catalysed one-pot synthesis of thiazole/benzothiazole-based isoquinolin-1(2H)-ones as potential cytotoxic and VEGFR-2 inhibitors 铜（II）催化一锅合成噻唑/苯并噻唑基异喹啉-1(2H)- 1作为潜在的细胞毒性和VEGFR-2抑制剂。

IF 4.7 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Bioorganic Chemistry

Pub Date : 2026-01-14 DOI: 10.1016/j.bioorg.2026.109506

Shivam Gupta , A. Ezhilmathe , Mary Sravani Galla , Chandraiah Godugu , Nagula Shankaraiah

A facile one-pot annulation method for the synthesis of diverse bioactive thiazole/benzothiazole-based isoquinolin-1(2H)-one frameworks was accomplished. This approach involves the Ullman-type coupling of halo-substituted phenyl thiazolamides with various alkyl cyanoacetates employing copper (II) chloride as sustainable catalyst and water as co-solvent. Further, in silico studies were revealed the compound's selectivity towards kinase inhibition. Eventually, these derivatives were evaluated for their in vitro cytotoxicity against various cancer cell lines such as MCF-7, HCT-116, A549, HEPG-2, and HEK-293 (normal cell line). Among them, compound 3h has displayed significant cytotoxicity with an IC₅₀ value of 7.75 ± 0.37 μM on HCT-116 cell line. Next, the compound 3h has also ability to induce apoptosis, which is examined through various staining assays like AO/EtBr, JC-1, and ROS. An ADP Glo kinase kit is utilised to evaluate the kinase inhibitory activity with most potent compound 3h, and showed an IC₅₀ value of 1.94 μM, which is comparable to that of the standard drug sunitinib (IC₅₀ of 400 nM). Finally, this straightforward one-pot annulation protocol is amenable in the generation of a library of new thiazole/benzothiazole-based heterocyclic compounds as potential cytotoxic and VEGFR-2 inhibitors in cancer drug discovery.

采用一锅环法制备了多种具有生物活性的噻唑/苯并噻唑基异喹啉-1(2H)- 1骨架。该方法采用氯化铜（II）作为可持续催化剂，水作为共溶剂，将卤代苯基噻唑胺与各种烷基氰乙酸酯进行ullman型偶联。此外，在计算机上的研究揭示了该化合物对激酶抑制的选择性。最后，对这些衍生物的体外细胞毒性进行了评估，以对抗各种癌细胞系，如MCF-7、HCT-116、A549、HEPG-2和HEK-293（正常细胞系）。其中化合物3h对HCT-116细胞株具有显著的细胞毒性，IC50值为7.75±0.37 μM。其次，化合物3h还具有诱导细胞凋亡的能力，这可以通过AO/EtBr、JC-1和ROS等染色试验来检验。利用ADP Glo激酶试剂盒对最有效化合物3h的激酶抑制活性进行评价，其IC50值为1.94 μM，与标准药物舒尼替尼的IC50值相当（IC50为400 nM）。最后，这种简单的一锅环化方案适用于新噻唑/苯并噻唑基杂环化合物库的生成，这些化合物可作为癌症药物发现中的潜在细胞毒性和VEGFR-2抑制剂。

{"title":"Copper(II)-catalysed one-pot synthesis of thiazole/benzothiazole-based isoquinolin-1(2H)-ones as potential cytotoxic and VEGFR-2 inhibitors","authors":"Shivam Gupta , A. Ezhilmathe , Mary Sravani Galla , Chandraiah Godugu , Nagula Shankaraiah","doi":"10.1016/j.bioorg.2026.109506","DOIUrl":"10.1016/j.bioorg.2026.109506","url":null,"abstract":"<div><div>A facile one-pot annulation method for the synthesis of diverse bioactive thiazole/benzothiazole-based isoquinolin-1(2<em>H</em>)-one frameworks was accomplished. This approach involves the Ullman-type coupling of halo-substituted phenyl thiazolamides with various alkyl cyanoacetates employing copper (II) chloride as sustainable catalyst and water as co-solvent. Further, <em>in silico</em> studies were revealed the compound's selectivity towards kinase inhibition. Eventually, these derivatives were evaluated for their <em>in vitro</em> cytotoxicity against various cancer cell lines such as MCF-7, HCT-116, A549, HEPG-2, and HEK-293 (normal cell line). Among them, compound <strong>3</strong><strong>h</strong> has displayed significant cytotoxicity with an IC<sub>50</sub> value of 7.75 ± 0.37 μM on HCT-116 cell line. Next, the compound <strong>3</strong><strong>h</strong> has also ability to induce apoptosis, which is examined through various staining assays like AO/EtBr, JC-1, and ROS. An ADP Glo kinase kit is utilised to evaluate the kinase inhibitory activity with most potent compound <strong>3</strong><strong>h</strong>, and showed an IC<sub>50</sub> value of 1.94 μM, which is comparable to that of the standard drug sunitinib (IC<sub>50</sub> of 400 nM). Finally, this straightforward one-pot annulation protocol is amenable in the generation of a library of new thiazole/benzothiazole-based heterocyclic compounds as potential cytotoxic and VEGFR-2 inhibitors in cancer drug discovery.</div></div>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"170 ","pages":"Article 109506"},"PeriodicalIF":4.7,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146027981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Discovery and mechanistic insights of novel Piperlongumine analogs as potent Bcr-Abl kinase inhibitors 新型胡椒明类似物作为有效的Bcr-Abl激酶抑制剂的发现和机制见解。

IF 4.7 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Bioorganic Chemistry

Pub Date : 2026-01-14 DOI: 10.1016/j.bioorg.2026.109508

Guanglong Zhang , Xuesha Long , Xue Yang , Chengpeng Li , Jiao Meng , Yuguo Zheng , Fuqiang Ren , Zhenchao Wang

In the exploration and discovery of potential anticancer candidates with novel mechanisms of action, a series of novel piperlongumine (PL) analogs was designed and synthesized. The majority of compounds demonstrated significant anti-proliferative effects in vitro, particularly with the 2-Cl analogs C1-C16. Notably, compound C5 exhibited the most potent anti-proliferative activity against K562 cells (IC₅₀ = 0.11 μM). Inspiringly, C5 was also found to selectively enhance the accumulation of ROS and induce apoptosis. Transcriptomic analysis revealed that the differentially expressed genes (DEGs) primarily encompassed apoptotic, PI3K/AKT signaling pathways, and other associated information. Molecular docking results revealed that C5 exhibited robust hydrogen bond interactions with specific amino acid residues in the Imatinib-Bcr-Abl^WT and Ponatinib-Bcr-Abl^T315I protein kinase models, suggesting a plausible binding model based on the docking scores. The findings suggest that C5 exhibits promising potential as a highly efficacious for an anti-leukemia agent, thereby providing a valuable avenue for further exploration and application.

在探索和发现具有新的作用机制的潜在抗癌候选药物的过程中，设计和合成了一系列新的胡椒隆明（PL）类似物。大多数化合物在体外表现出显著的抗增殖作用，特别是对2-Cl类似物C1-C16。其中化合物C5对K562细胞的抗增殖活性最强（IC50 = 0.11 μM）。令人鼓舞的是，C5还被发现选择性地增加ROS的积累并诱导细胞凋亡。转录组学分析显示，差异表达基因（DEGs）主要包含凋亡、PI3K/AKT信号通路和其他相关信息。分子对接结果显示，C5在Imatinib-Bcr-AblWT和Ponatinib-Bcr-AblT315I蛋白激酶模型中与特定氨基酸残基表现出强大的氢键相互作用，这表明基于对接分数的结合模型是合理的。研究结果表明，C5作为一种高效的抗白血病药物具有良好的潜力，从而为进一步的探索和应用提供了宝贵的途径。

{"title":"Discovery and mechanistic insights of novel Piperlongumine analogs as potent Bcr-Abl kinase inhibitors","authors":"Guanglong Zhang , Xuesha Long , Xue Yang , Chengpeng Li , Jiao Meng , Yuguo Zheng , Fuqiang Ren , Zhenchao Wang","doi":"10.1016/j.bioorg.2026.109508","DOIUrl":"10.1016/j.bioorg.2026.109508","url":null,"abstract":"<div><div>In the exploration and discovery of potential anticancer candidates with novel mechanisms of action, a series of novel piperlongumine (<strong>PL</strong>) analogs was designed and synthesized. The majority of compounds demonstrated significant anti-proliferative effects in vitro, particularly with the 2-Cl analogs <strong>C1-C16</strong>. Notably, compound <strong>C5</strong> exhibited the most potent anti-proliferative activity against K562 cells (IC<sub>50</sub> = 0.11 μM). Inspiringly, <strong>C5</strong> was also found to selectively enhance the accumulation of ROS and induce apoptosis. Transcriptomic analysis revealed that the differentially expressed genes (DEGs) primarily encompassed apoptotic, PI3K/AKT signaling pathways, and other associated information. Molecular docking results revealed that <strong>C5</strong> exhibited robust hydrogen bond interactions with specific amino acid residues in the Imatinib-Bcr-Abl<sup>WT</sup> and Ponatinib-Bcr-Abl<sup>T315I</sup> protein kinase models, suggesting a plausible binding model based on the docking scores. The findings suggest that <strong>C5</strong> exhibits promising potential as a highly efficacious for an anti-leukemia agent, thereby providing a valuable avenue for further exploration and application.</div></div>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"170 ","pages":"Article 109508"},"PeriodicalIF":4.7,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146027893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0